Autologous Volar Fibroblast Injections for Amputation

This study is looking at a treatment called Autologous Volar Fibroblast Injection for people who have had a transtibial (below-the-knee) amputation. This treatment uses your own skin cells, called fibroblasts, taken from your palm or sole (volar skin), to see if they can make the skin on your residual limb firmer. Researchers want to know if this treatment is safe and if it helps improve skin firmness. You could be eligible if you are 18-75 years old, have a transtibial amputation, and use a prosthesis. The study plans to enroll 20 participants, but its current recruitment status is unclear.

Study design
This study will enroll 20 adults and randomly assign them to either receive the fibroblast injections or a control treatment. This means you have an equal chance of receiving the active treatment or a placebo.
What's involved
You would undergo a skin biopsy to collect cells, have injection sites tattooed, and receive injections on your residual limb over 1 to 3 days within one week.
Compensation
Not stated in the trial record.
Follow-up
The study will assess safety and skin firmness from when you start until 3 months after your injection visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04839497

Multicenter Trial Evaluating the Safety and Efficacy of Autologous Volar Fibroblast Injection Into the Terminal Limb of Amputees.

Recruiting
PHASE2Ages 18–75InterventionalTreatment
Major Extremity Trauma Research Consortium
~20 participants
Updated 2025-10-14 on ClinicalTrials.gov
What's tested:Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety assessment of complications and adverse events associated with Volar Fibroblast injections
Measured over 3 months from the injection visit
+1 more outcome measured
Amputation

NCT04839497

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Johns Hopkins Hospital

    Baltimore, Marylandstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Opens a ready-to-send draft in your own email app — review before sending.

  • Safety assessment of complications and adverse events associated with Volar Fibroblast injections3 months from the injection visit

    Safety will be evaluated by routinely assessing all complications at each study visit. Minor and expected complications may include local injection reactions like bruising and erythema, swelling and pain. Minor complications that are not expected include local small hemorrhage (x\<1mL), edema, nodules, papules, irritation, dermatitis, pruritus, and cellulitis. Serious Adverse Events are defined as unexpected AND serious AND related or possibly related to the study treatment. These may include but are not limited to osteomyelitis.

  • Efficacy of autologous volar fibroblasts for increasing skin firmness in individuals with a transtibial amputation.Baseline through 3 months from the injection visit

    Efficacy will be determined by treatment group difference in the pre- post-change in skin firmness at three months post injection. Skin firmness is the level of resistance as measured by a non-invasive hand-held durometer